Table 1.
Characteristics per patient.
| Patient No. | Age/Gender | MM subtype | High-risk cytogenetics at diagnosis and/or "high-risk" feature at enrolment | R-ISS at diagnosis | No. of prior regim ens | No. of prior auto-HCT | Disease status prior to allo- HCT | Daysfrom last auto toallo- HCT | Donor type | Disease status at day +80–90 | Current status (days after allo-HCT) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 44/M | Kappa light chaln | Progressive disease after auto-HCT | 1 | 2 | 1 | VGPR | 457 | MUD | sCR | Relapsed at day +1 244, alive on other therapy |
| 2 | 53/F | IgG kappa | Persistent disease after auto-HCT and β2M ≥3.5 g/dL | II | 4 | 1 | VGPR | 85 | MUD | VGPR | Relapsed at day +1 169, alive on other therapy |
| 3 | 58/M | IgA lambda | t(4;14), −1p, persistent disease after auto-HCT requiring radiatlon | II | 1 | 1 | CR | 135 | MUD | CR | Alive and disease-free |
| 4 | 55/F | IgG kappa | Primary refractory/perslstent disease after auto-HCT | NE | 4 | 1 | VGPR | 128 | MUD | VGPR | Alive and disease-free |
| 5 | 49/M | IgA lambda | Progressive disease after auto-HCT | NE | 3 | 2 | CR | 155 | MUD | CR | Alive and disease-free |
| 6 | 41/M | IgG kappa | Primary refractory/perslstent disease after auto-HCT | NE | 2 | 1 | VGPR | 237 | MUD | VGPR | Alive and disease-free |
| 7 | 49/M | IgG kappa | t(4;14), −1p, +1q | II | 2 | 1 | VGPR | 127 | MUD | Relapse | Relapsed at day +105, died of relapse at day +185 |
| 8 | 57/F | IgG lambda | t(4;14), Progressive disease after auto- HCT | II | 4 | 2 | Relapse | 424 | MRD | VGPR | Relapsed at day +1 224, alive on other therapy |
| 9 | 61/F | IgA lambda | −1p, +1q, t(14;16), −17p | III | 1 | 1 | sCR | 142 | MUD | sCR | Alive and disease-free |
| 10 | 56/M | IgG lambda | t(4;14) | II | 2 | 1 | sCR | 95 | MUD | Relapse | Relapsed at day +84, died of relapse at day +587 |
| 11 | 55/M | IgA kappa | Persistent disease after auto-HCT, +1q | NE | 1 | 1 | CR | 176 | MRD | sCR | Alive and disease-free |
| 12 | 58/F | IgA kappa | −17p, Progressive disease after auto- HCT | II | 2 | 2 | CR | 75 | MUD | sCR | Died of resplratory fallure In the setting of liver GVHD wlthout relapse at day +262 |
| 13 | 63/F | Prima ry PCL | −17p, −13 by karyotype | II | 2 | 1 | Relapse | 95 | MRD | Relapse | Relapsed at day +63, died of relapse at day +89 |
| 14 | 59/M | IgG kappa | Hypodiploidy (monosomy 7), −13 by karyotype, +1q, −17p | II | 1 | 1 | VGPR | 59 | MUD | VGPR | Alive and disease-free |
MM = multiple myeloma; PCL= plasma celi leukemia; R-ISS = Revised International Staglng System; NE = not evaluable; sCR = stringent complete response; CR = complete response; VGPR = very good partlal response; MUD = matched unrelated donor; MRD = matched related donor